Scott Gottlieb testifies on Capitol Hill in 2017 (Photo: AP Images / Graphics: Endpoints News)
October 30, 2019 06:12 AM EDT
Financing

Why Scott Got­tlieb, ven­ture cap­i­tal­ist, sees op­por­tu­ni­ty in an­tibi­otics

Jason Mast

Editor

A drug de­vel­op­er in­vestor say­ing she’s very ex­cit­ed about an­tibi­otics right now is about the equiv­a­lent of a trad­er telling you in 2008 the hous­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times